Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

IST/GENIL stock hub

IST/GENIL has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

IST/GENILis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

38.7B

Istanbul Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

IST/GENIL

In the news

Latest news · IST/GENIL

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 13.7P50 15.1P75 15.3

Trailing P/E56.6

P25 16.6P50 25.2P75 56.6

ROE8.1

P25 -2.4P50 3.5P75 11.2

ROIC11

P25 -0.7P50 4.3P75 13.6

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All IST/GENIL market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

220

Groups with data

Currency

TRY

Showing 220 of 220 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Turkey
Country code	TR
Employees	682
Employees Change	63%
Employees Change Percent	10.18
Enterprise value	TRY 39.7B
Exchange	Istanbul Stock Exchange
Financial currency	TRY
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	TREGENL00024
Last refreshed	2026-05-10
Market cap	TRY 38.7B
Price	TRY 8.6
Price currency	TRY
Rev Per Employee	28,125,286.6x
Sector	Healthcare
Sic	2834
Symbol	ist/GENIL
Website	https://www.genilac.com.tr

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.1%
EV Earnings	48.74x
EV/EBIT	17.07x
EV/EBITDA	13.84x
EV/FCF	45.77x
EV/Sales	2.07x
FCF yield	2.24%
P/B ratio	3.75x
P/E ratio	56.63x
P/S ratio	2.02x
PE Ratio3 Y	71.97x
PE Ratio5 Y	50.19x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	12.12%
EBITDA Margin	14.95%
FCF margin	4.52%
Gross margin	20.86%
Gross Profit	TRY 4B
Gross Profit Growth	7.85%
Gross Profit Growth Q	21.7%
Gross Profit Growth3 Y	28.15%
Gross Profit Growth5 Y	64.48%
Net Income	TRY 814.4M
Net Income Growth	318.51%
Net Income Growth Q	175.81%
Net Income Growth3 Y	8.37%
Net Income Growth5 Y	31.36%
Pretax Margin	7.75%
Profit Margin	4.25%
Profit Per Employee	TRY 1.2M
ROA	8.14
Roa5y	9.92
ROCE	19.92
ROE	8.1
Roe5y	15.11
ROIC	11.01
Roic5y	22.89

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	9.02%
Cagr3y	46.83%
Div CAGR3	-28.86%
EPS Growth	251.2
EPS Growth Q	56.08
EPS Growth3 Y	2.21
EPS Growth5 Y	-11.37
FCF Growth	-60.66%
FCF Growth Q	-18.67%
FCF Growth3 Y	9.37%
FCF Growth5 Y	126.37%
OCF Growth	-43.05%
OCF Growth Q	16.26%
OCF Growth3 Y	18.47%
OCF Growth5 Y	71.99%
Revenue Growth	-0.59x
Revenue Growth Q	0.46x
Revenue Growth3 Y	21.71x
Revenue Growth5 Y	54.91x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	TRY 1.07
Assets	TRY 19.5B
Cash	TRY 2.1B
Current Assets	TRY 9.9B
Current Liabilities	TRY 7.8B
Debt	TRY 3.1B
Debt EBITDA	TRY 1.09
Debt Equity	TRY 0.3
Debt FCF	TRY 3.62
Equity	TRY 10.3B
Interest Coverage	2.52
Liabilities	TRY 9.1B
Long Term Assets	TRY 9.6B
Long Term Liabilities	TRY 1.3B
Net Cash	TRY -999.3M
Net Cash By Market Cap	TRY -2.58
Net Debt EBITDA	TRY 0.35
Net Debt Equity	TRY 0.1
Net Debt FCF	TRY 1.15
Tangible Book Value	TRY 10.1B
Tangible Book Value Per Share	TRY 1.27
WACC	4.86

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.27
Inventory Turnover	6.39
Net Working Capital	TRY 2.9B
Quick ratio	0.68
Working Capital	TRY 2.1B
Working Capital Turnover	TRY 9.16

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-19.18%
Dividend Growth	0%
Dividend Growth Years	0%
Dividend per share	TRY 0.05
Dividend Years	4
Dividend Yield	0.56%
Ex Div Date	2025-11-12
Last Dividend	TRY 0.01

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	9.01%
200-day SMA	11.1
3Y total return	216.6%
50-day SMA	9.51
50-day SMA vs 200-day SMA	50under200
All Time High	14.93
All Time High Change	-42.41%
All Time High Date	2025-10-13
All Time Low	0.79
All Time Low Change	991.37%
All Time Low Date	2021-08-05
ATR	0.56
Beta	-0.05
Beta1y	-0.41
Beta2y	-0.28
Ch YTD	-35.18
High	9.44
High52	14.93
High52 Date	2025-10-13
High52ch	-42.41%
Low	8.55
Low52	7.12
Low52 Date	2026-02-24
Low52ch	20.79%
Ma50ch	-9.59%
Price vs 200-day SMA	-22.52%
RSI	30.24
RSI Monthly	50.13
RSI Weekly	41.64
Sharpe ratio	0.21x
Sortino ratio	0.42
Total Return	-18.62%
Tr YTD	-35.18
Tr1m	-17.31%
Tr1w	-3.37%
Tr3m	6.7%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	TRY 2.3B
Operating Income Growth	62.27
Operating Income Growth Q	753.2
Operating Income Growth3 Y	23.22
Operating Income Growth5 Y	59.37
Operating margin	12.12

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	260,220,000%
Net Borrowing	1,633,485,958
Shares Insiders	75.47%
Shares Institutions	8.21%
Shares Out	4,500,000,000
Shares Qo Q	76.71%
Shares Yo Y	19.18%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	TRY 867.2M
Average Volume	67,329,181.5x
Bv Per Share	1.3
CAPEX	TRY -618.7M
Ch1m	-17.31
Ch1w	-3.37
Ch1y	8.86
Ch3m	6.7
Ch3y	202.3
Ch6m	-26.99
Change	0.12%
Change From Open	-4.23
Close	8.59
Days Gap	4.54
Depreciation Amortization	541,544,284
Dollar Volume	4,103,032,480
Earnings Date	2026-05-15
EBIT	TRY 2.3B
EBITDA	TRY 2.9B
EPS	TRY 0.15
F Score	6
FCF	TRY 867.2M
FCF EV Yield	2.18x
FCF Per Share	TRY 0.19
Financing CF	722,348,140
Fiscal Year End	December
Founded	1,997
Graham Number	2.10741
Graham Upside	-75.5
Income Tax	TRY 680.2M
Investing CF	-2,703,941,802
Is Primary Listing	1
Last Earnings Date	2026-03-03
Last Report Date	2025-12-31
Last Split Date	2026-02-10
Last Split Type	Forward
Lynch Fair Value	TRY 3.8
Lynch Upside	-55.85
Ma150	10.77
Ma150ch	-20.16%
Ma20	9.72
Ma20ch	-11.51%
Net CF	-616,741,930
Next Earnings Date	2026-05-15
Open	8.98
P FCF Ratio	44.62
P OCF Ratio	26.04
Payment Date	2025-11-14
Position In Range	5.62
Ppne	5,503,156,432
Price Date	2026-05-08
Price EBITDA	TRY 13.5
Ptbv Ratio	3.82
Relative Volume	7.09x
Revenue	19,181,445,462x
Tax By Revenue	3.55x
Tax Rate	45.78%
Tr6m	-26.95%
Volume	477,096,800
Z Score	4.94

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

IST/GENIL dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.6%

$0.05 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

0 consecutive years of growth

Total shareholder yield

-18.6%

Next ex-dividend date: 2025-11-12

Performance

IST/GENIL stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns IST/GENIL?

Insider, institutional, and short-interest positioning.

Institutional ownership

+8.2%

Share of float held by funds and institutions

Insider ownership

+75.5%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+19.2%

Negative means the company is buying back shares.

Technical

IST/GENIL momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

30.2

Neutral momentum band

Price vs 200-day MA

-22.5%

50/200-day relationship not available

Beta (5Y)

-0.05

Less volatile than the market

Sharpe ratio

0.21

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About IST/GENIL

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ist/GENIL stock rating?

ist/GENIL is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ist/GENIL analysis?

The full report lives at /stocks/ist/GENIL/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ist/GENIL?

The latest report frames ist/GENIL around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ist/GENIL page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.